Stemline Therapeutics, Inc. (STML) Short Interest Update
Stemline Therapeutics, Inc. (NASDAQ:STML) was the target of a significant decline in short interest in January. As of January 31st, there was short interest totalling 744,915 shares, a decline of 44.6% from the January 13th total of 1,344,011 shares. Based on an average daily trading volume, of 488,390 shares, the days-to-cover ratio is presently 1.5 days. Approximately 3.5% of the shares of the stock are sold short.
A number of analysts have recently commented on the company. Roth Capital restated a “buy” rating and issued a $32.00 price objective on shares of Stemline Therapeutics in a research report on Wednesday, December 7th. Wedbush restated an “outperform” rating and issued a $15.00 price objective on shares of Stemline Therapeutics in a research report on Tuesday, December 6th. Zacks Investment Research cut Stemline Therapeutics from a “hold” rating to a “sell” rating in a research report on Wednesday, January 18th. Ladenburg Thalmann Financial Services restated a “buy” rating on shares of Stemline Therapeutics in a research report on Monday, February 6th. Finally, Jefferies Group LLC set a $16.00 price objective on Stemline Therapeutics and gave the company a “buy” rating in a research report on Friday, February 3rd. One research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company. The company presently has an average rating of “Buy” and a consensus price target of $21.00.
Shares of Stemline Therapeutics (NASDAQ:STML) opened at 6.40 on Friday. The company’s 50 day moving average price is $9.87 and its 200 day moving average price is $10.46. Stemline Therapeutics has a 12 month low of $3.88 and a 12 month high of $14.60. The stock’s market capitalization is $114.21 million.
In other news, insider David Gionco sold 3,593 shares of the business’s stock in a transaction that occurred on Thursday, January 19th. The stock was sold at an average price of $11.46, for a total value of $41,175.78. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, COO Kenneth Hoberman sold 9,110 shares of the business’s stock in a transaction that occurred on Tuesday, January 10th. The shares were sold at an average price of $13.82, for a total value of $125,900.20. The disclosure for this sale can be found here. 16.70% of the stock is owned by insiders.
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. California State Teachers Retirement System increased its position in Stemline Therapeutics by 6.1% in the second quarter. California State Teachers Retirement System now owns 35,349 shares of the biopharmaceutical company’s stock worth $239,000 after buying an additional 2,019 shares in the last quarter. Emerald Acquisition Ltd. bought a new stake in Stemline Therapeutics during the second quarter worth $129,000. Acadian Asset Management LLC bought a new stake in Stemline Therapeutics during the third quarter worth $400,000. State Treasurer State of Michigan bought a new stake in Stemline Therapeutics during the third quarter worth $217,000. Finally, Oak Ridge Investments LLC boosted its stake in Stemline Therapeutics by 26.3% in the third quarter. Oak Ridge Investments LLC now owns 12,796 shares of the biopharmaceutical company’s stock worth $139,000 after buying an additional 2,663 shares during the last quarter. Hedge funds and other institutional investors own 37.76% of the company’s stock.
“Stemline Therapeutics, Inc. (STML) Short Interest Update” was first reported by Daily Political and is the sole property of of Daily Political. If you are reading this piece on another site, it was stolen and reposted in violation of US & international copyright and trademark legislation. The legal version of this piece can be accessed at http://www.dailypolitical.com/2017/02/16/stemline-therapeutics-inc-stml-short-interest-update.html.
About Stemline Therapeutics
Stemline Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing oncology therapeutics. The Company is developing approximately three clinical stage product candidates, including SL-401, SL-701 and SL-801. SL-401 is a targeted therapy directed to the interleukin-3 receptor (IL-3R) (CD123), present on a range of hematologic cancers.
Receive News & Ratings for Stemline Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stemline Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.